Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesaglitazar Monotherapy in Drug-Naïve Type 2 Diabetes
NCT00252772Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tesaglitazar in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by AstraZeneca. Primary endpoint: Glycosylated Hemoglobin A1c at 24 weeks. Started Sep 2004; status: terminated.
02
Drugs
tesaglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00252772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00252772.